Aeolus Pharmaceuticals Inc. provided revenue guidance for the fiscal year 2012. The company announced that it received from the Biomedical Advanced Research and Development Authority a Notice of intent to exercise options valued at $9.1 million. As a result of the notice of intent to exercise the new options, the company expects revenue for fiscal year 2012 to be in the range of $9 to 11 million, up from $4.8 million in fiscal year 2011.